You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment‐resistant depression
|
|---|---|
| Published in |
Bipolar Disorders, January 2023
|
| DOI | 10.1111/bdi.13296 |
| Pubmed ID | |
| Authors |
Giovanni Martinotti, Bernardo Dell'Osso, Giorgio Di Lorenzo, Giuseppe Maina, Alessandro Bertolino, Massimo Clerici, Stefano Barlati, Gianluca Rosso, Marco Di Nicola, Matteo Marcatili, Giacomo d'Andrea, Clara Cavallotto, Stefania Chiappini, Sergio De Filippis, Giuseppe Nicolò, Pasquale De Fazio, Ileana Andriola, Raffaella Zanardi, Domenica Nucifora, Stefania Di Mauro, Roberta Bassetti, Mauro Pettorruso, Roger S. McIntyre, Stefano L. Sensi, Massimo di Giannantonio, Antonio Vita, the REAL‐ESK Study Group |
| Abstract |
Bipolar depression accounts for most of the disease duration in type I and type II bipolar disorder (BD), with few treatment options, often poorly tolerated. Many individuals do not respond to first-line therapeutic options, resulting in treatment-resistant bipolar depression (B-TRD). Esketamine, the S-enantiomer of ketamine, has recently been approved for treatment-resistant depression (TRD), but no data are available on its use in B-TRD. to compare the efficacy of esketamine in two samples of unipolar and bipolar TRD, providing preliminary indications of its effectiveness in B-TRD. Secondary outcomes included the evaluation of the safety and tolerability of esketamine in B-TRD, focusing on the average risk of an affective switch. Thirty-five B-TRD subjects treated with esketamine nasal spray were enrolled and compared with 35 TRD patients. Anamnestic data and psychometric assessments (Montgomery-Asberg Depression Rating Scale/MADRS, Hamilton-depression scale/HAM-D, Hamilton-anxiety scale/HAM-A) were collected at baseline (T0), at one month (T1) and three months (T2) follow-up. A significant reduction in depressive symptoms was found at T1 and T2 compared to T0, with no significant differences in response or remission rates between subjects with B-TRD and TRD. Esketamine showed a greater anxiolytic action in subjects with B-TRD than in those with TRD. Improvement in depressive symptoms was not associated with treatment-emergent affective switch. Our results supported the effectiveness and tolerability of esketamine in a real-world population of subjects with B-TRD. The low risk of manic switch in B-TRD patients confirmed the safety of this treatment. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 25% |
| Canada | 1 | 25% |
| Unknown | 2 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 50% |
| Scientists | 2 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 35 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 35 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Professor > Associate Professor | 5 | 14% |
| Student > Master | 5 | 14% |
| Student > Bachelor | 4 | 11% |
| Unspecified | 4 | 11% |
| Student > Postgraduate | 3 | 9% |
| Other | 5 | 14% |
| Unknown | 9 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 43% |
| Unspecified | 4 | 11% |
| Neuroscience | 3 | 9% |
| Nursing and Health Professions | 2 | 6% |
| Biochemistry, Genetics and Molecular Biology | 1 | 3% |
| Other | 0 | 0% |
| Unknown | 10 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 19. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 January 2024.
All research outputs
#1,897,356
of 25,238,182 outputs
Outputs from Bipolar Disorders
#95
of 1,177 outputs
Outputs of similar age
#39,184
of 469,561 outputs
Outputs of similar age from Bipolar Disorders
#2
of 20 outputs
Altmetric has tracked 25,238,182 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,177 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.8. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 469,561 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 20 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.